Skip to content

Ecat.nl

Ecat.nl

Home
Docs
Parameter
Laboratory Tests
Fibrinolysis: D-Dimer

Analytical Information

Analytical performance specifications for hemostasis parameters
Assuring quality in the postanalytical phase
Comparison of two statistical software programs for determining reference intervals of screening coagulation assays
Critical pre-examination variables in hemostasis testing
Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine
Focus Article: update on platelet aggregation testing
Literature Review: Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
Literature Review: The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
Risk management for laboratory testing
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
The use of quality indicators for the pre-analytical phase

Assays

Clotting factor (II, V, VII and X)
Clotting factor (VIII, IX, XI and XII)
Factor VIII Inhibitor
- Factor VIII deficient plasma
- Normal pooled plasma
Factor XIII
- Factor XIII activity
- Factor XIII antigen
Fibrinolysis
Heparin Induced Thrombocytopenia
- Immunological test
Homocysteine
- Method
Screening
Thrombophilia
Von Willebrand Factor

Cases

A severe haemophilia A patient treated with emicizumab, case study
Acquired haemophilia A
Acquired Hemophilia A, case study
Case Report: acquired Glanzmann’s thrombasthenia
Dysfibrinogenemia, case study
Factor V Inhibitor
Haemophilia A and treatment, case study
Haemophilia B and treatment, case study
Trauma-Induced Coagulopathy, case study
Von Willebrand Disease type 1, case study
Von Willebrand Disease type 2B, case study
Von Willebrand Jürgens syndrome type I, case study 2016
Von Willebrand Jürgens syndrome type I, case study 2019

ECAT Documentation

Meetings
- Meeting
- Webinars
Publications
- 1. Publication list ECAT Foundation
Special Issue

Guidelines

Diagnosis and classification of factor XIII deficiencies, SSC recommendation
Guidance for INR and D-dimer testing using point of care testing in primary care, ICSH recommendations
Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls, ICSH recommendations
ICSH Recommendations for Hemostasis Critical Values, Tests, and Reporting
ICSH Recommendations for laboratory measurement of ADAMTS13
ICSH Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
Laboratory guidance for the evaluation of haemostasis analyser-reagent test systems. Part 1: Instrument-specific issues and commonly used coagulation screening tests. ICSH Recommendations
Laboratory guidance for the verification of haemostasis analyser-reagent test systems. Part 2: Specialist tests and calibrated assays, ICSH recommendations
Recommendations for collection of blood samples for coagulation testing, ICSH recommendations
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Recommendations for processing of blood samples for coagulation testing, ICSH recommendations
Recommendations on fibrinogen assays, thrombin clotting time and related tests in the investigation of bleeding disorders, ICSH recommendations
Thrombin generation measurement in haemophilia, SSC recommendation
Update Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, ICSH recommendations

Haemostatic Cascade

Activation of Platelets by Thrombin
Activation of Protein C by Thrombin
Activation of TAFI by Thrombin
Amino Acid structure of Natural Hirudin
Coagulation Pathways (All Components)
Fibrinolytic Pathway
Intrinsic Pathway APTT
Nucleotide sequences of RNA Codons Encoding for Amino Acids
TF Pathway (Extrinsic) with Common Pathway (PT)

Parameter

Laboratory Tests
Test Information

Quality Issues

Algorithm A, a new statistical approach for the evaluation of survey results
Assuring quality in the postanalytical phase
Bayesian strategy in long-term IQC results management: practical interest and compliance with standards
Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine
Does quality matter?
ECAT Information: Results of the surveys for heparin monitoring
External quality assessment for Rivaroxaban and Dabigatran
External quality assessment / proficiency testing for platelet function disorders
External quality assessment for Factor VIII and Factor IX
External quality assessment for Factor XIII
External quality assessment for immunological Heparin-Induced Thrombocytopenia testing
External quality assessment for von Willebrand Factor laboratory analysis
External Quality Assessment in haemostasis
Internal Quality Control for Coagulation: Repeating the same mistakes as chemistry? Or leaping ahead into the 21st century?
Interpretation of the Z-score
Long-term evaluation of EQA results
Quality Assurance of replacement therapy and future perspectives
Risk management for laboratory testing
The between-laboratoy variation of Factor VIII inhibitor testing
The relevance of accreditation for medical laboratories: An added value for patient care
The use of quality indicators for the pre-analytical phase
Validation of methods in hemostasis testing: a practical approach
Wet Workshop on Platelet Function Testing

Surveys and Studies

A severe haemophilia A patient treated with emicizumab, case study
Acquired Hemophilia A, case study
Dysfibrinogenemia, case study
External quality assessment for Rivaroxaban and Dabigatran
External quality assessment for Factor VIII and Factor IX
External quality assessment for Factor XIII
External quality assessment for immunological Heparin-Induced Thrombocytopenia testing
External quality assessment for von Willebrand Factor laboratory analysis
Haemophilia A and treatment, case study
Haemophilia B and treatment, case study
The between-laboratoy variation of Factor VIII inhibitor testing
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Trauma-Induced Coagulopathy, case study
Von Willebrand Disease type 1, case study
Von Willebrand Disease type 2B, case study
Von Willebrand Jürgens syndrome type I, case study 2016
Von Willebrand Jürgens syndrome type I, case study 2019

Terminology

Terminology

Fibrinolysis: D-Dimer

Related items

Guidelines : 1

Guidance for INR and D-dimer testing using point of care testing in primary care, ICSH recommendations

Analytical Information : 1

Analytical performance specifications for hemostasis parameters

Laboratory Tests : 68

Fibrinolysis: Global Fibrinolytic Capacity (GFC) and Clot Formation and Lysis (CloFAL)

ReoRox G2

Thromboelastography (TEG) & Rotational Thromboelastometry (ROTEM)

Thrombin Generation (Clotting-based, Chromogenic and Fluorogenic)

Prothrombin Fragment 1+2 (F1+2)

Heparin Cofactor II (HCII)

The Bleeding Time (BT)

International Sensitivity Index (ISI) & The International Normalised Ratio (INR)

Reptilase (Batroxobin) Time

Prothrombinase-induced Clotting Test (PiCT)

Protamine Sulphate Neutralisation Test

Ecarin Clotting Time

Heparin Induced Thrombocytopenia (HIT), Anti-Platelet Factor 4 (PF4)

ADAMTS13 activity, antigen and inhibitor

Anti-Xa (Clotting-based and Chromogenic)

Activated Clotting Time (ACT)

Factor V Leiden (F5 Arg506Gln)

Prothrombin (F2) G20210A Mutation

Fibrinolysis: Venous Occlusion Test

Fibrinolysis: Urokinase-type Plasminogen Activator (u-PA)

Fibrinolysis: Thrombin Activatable Fibrinolysis Inhibitor (TAFI)

Fibrinolysis: Tissue-type Plasminogen Activator (t-PA)

Fibrinolysis: Plasminogen Activator Inhibitor Type 1 (PAI-1): Serpin E1

Fibrinolysis: Plasminogen (Plg)

Fibrinolysis: α2-Plasmin Inhibitor

Fibrinolysis: Euglobulin Clot Lysis Time (ECLT)

Fibrinolysis: Fibrinogen Degradation Products (FDP)

Anticardiolipin (aCL) and Anti-β2-Glycoprotein I (Anti-β2GPI)

Lupus Anticoagulant (LA): Dilute Thromboplastin Inhibition (DTI)

Lupus Anticoagulant (LA): Textarin:Ecarin Ratio and Taipan:Ecarin Ratio

Lupus Anticoagulant (LA): Taipan Venom Time

Lupus Anticoagulant (LA): Silica Clotting Time (SCT)

Lupus Anticoagulant (LA): Kaolin Clotting Time (KCT)

Lupus Anticoagulant (LA): Dilute Russell Viper Venom Time (dRVVT)

Homocysteine (Hcy)

Protein C (ProC) Global Assay

Activated Protein C resistance (APC-R)

Protein S (Clotting-based and Immunological)

Protein C (Clotting-based, Immunological and Chromogenic)

Antithrombin (Chromogenic and Immunological)

Platelet Function: Platelet Procoagulant Activity (PCA)

Platelet Function: Flow Cytometry

Platelet Function: Platelet Nucleotides

Global Thrombosis Test (GTT)

Platelet Function: VerifyNow

Platelet Function: PFA-100/200

Platelet Function: Impedance Platelet Aggregometry

Platelet Function: Light Transmission Aggregometry (LTA)

Von Willebrand Factor Propeptide (VWFpp)

Von Willebrand Factor (VWF) Multimers

Ristocetin-Induced Platelet Agglutination (RIPA)

Von Willebrand Factor Activity (VWF:Act)

Von Willebrand Factor Ristocetin Cofactor (VWF:RCo)

Von Willebrand Collagen Binding (VWF:CB)

Factor VIII Binding (VWF:FVIIIB)

Von Willebrand Factor antigeen (VWF:Ag)

Von Willebrand Factor (VWF) Inhibitor

Factor VIII inhibitor

Factor XIII

Factor IX (Chromogenic)

Factor VIII (Clotting-based and Chromogenic)

Factor X Assay (RVV)

Factor Assays APTT-Based (1-Stage)

Factor Assays PT-Based (1-Stage)

Fibrinogen

Thrombin Time (TT)

Activated Partial Thromboplastin Time (APTT)

Prothrombin Time (PT)

Fibrinolysis : 7

t-PA activity

t-PA antigen

PAI-1 activity

PAI-1 antigen

Plasmin inhibitor activity

Plasminogen antigen

Plasminogen activity

Thrombophilia : 1

D-Dimer

Clotpedia

© 2022 ECAT Clotpedia All Rights Reserved

ECAT Foundation
P.O. Box 107
2250 AC Voorschoten | The Netherlands
Email: info@ecat.nl
T: +31 (0) 71 3030 910 | F: +31 (0) 71 3030 919

Clotpedia Support Form

Success

Thank you for submitting your message